Report Highlights
Leukemia is defined as a cancer observed in white blood cell (WBC) in our body. White blood cell helps our body to fight against infection caused by harmful pathogen. Bone marrow is the center for the production of RBC (carry oxygen to all part of body), WBC (fight against infection) and platelets (help in blood clotting). Our bone marrow produces abnormal WBC when we are suffering from leukemia. Moreover abnormal WBCs are not able to perform normal functioning or WBC loses its ability to fight against infection. Etiology for leukemia includes artificial ionizing radiation, benzene and petrochemicals, alkylation chemotherapy agents, genetic predisposition and electromagnetic energy. Genetic predisposition and electromagnetic energy is the most common cause of leukemia observed among people. Signs and symptoms of leukemia includes a new lump or swollen gland in neck and arm, frequent nosebleed, pain in the bone, night sweat and frequent fever. Leukemia can be diagnosed by bone marrow tests, platelet count and WBC (white blood cell) differential count test. Leukemia can be treated by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy.
Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.
The global market for leukemia treatment can be segmented as follows:
Based on the developmental and progression rate
- Chronic leukemia
- Acute leukemia
Chronic leukemia is a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia and anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants and biologic therapies.
Acute myeloid leukemia develops at a speedy pace and is found in the blood and bone marrow. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin.Treatment for acute leukemia includes chemotherapy, stem cell transplants and biologic therapies.
About 90% of the leukemia cases occur in the middle age and progresses with the aging. Therefore, leukemia therapeutics market is poised to grow with the rise in aging population and increasing incidences of leukemia. Drugs such as Bosulif, Gleevec, Sprycel andIclusigare commercially available for the treatment of leukemia. Gleevec was the first leukemia drug introduced in 2001, since then there has been a revolutionary change in the quality life of patients as compared to the former chemotherapy drugs.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 2 billion mark in 2050 stated by United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.However adverse event (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand of leukemia therapeutics market.
North America dominates the global market for leukemia therapeutics treatment due to high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market share due to its large geriatric population base. In addition Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics market respectively due to less prevalence rate of leukemia and lack of proper healthcare facilities in few Asian and African countries.
North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. Leukemia therapeutics market will grow significantlyand the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.
Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.
This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, product types and distribution channels.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2012 - 2014
- Market Size & Forecast 2015 to 2025
- Supply & Demand Value Chain
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
- Market Drivers and Restraints
Regional analysis includes
- North America
- US & Canada
- Latin America
- Brazil, Argentina & Others
- Western Europe
- EU5
- Nordics
- Benelux
- Eastern Europe
- Asia Pacific
- Australia and New Zealand (ANZ)
- Greater China
- India
- ASEAN
- Rest of Asia Pacific
- Japan
- Middle East and Africa
- GCC Countries
- Other Middle East
- North Africa
- South Africa
- Other Africa
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Synopsis
Report Metrics | Details |
Base year considered | 2022 |
Forecast period considered | 2022-2032 |
Units considered | $ Million |
Segments covered | By Therapy Type, By Route of Administration, By Disease Type, By End-User, By Region |
Industry covered | Healthcare |
Countries covered | U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
Companies studied |
|
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics of the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
Must-have information for market players to sustain and enhance their market footprint
- Table 1 : Global Market Value (US$ Mn) Forecast by Region, 2017-2032
- Table 2 : Global Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 3 : Global Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 4 : Global Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 5 : Global Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 6 : North America Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 7 : North America Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 8 : North America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 9 : North America Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 10 : North America Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 11 : Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 12 : Latin America Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 13 : Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 14 : Latin America Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 15 : Latin America Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 16 : Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 17 : Europe Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 18 : Europe Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 19 : Europe Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 20 : Europe Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 21 : East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 22 : East Asia Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 23 : East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 24 : East Asia Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 25 : East Asia Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 26 : South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 27 : South Asia & Pacific Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 28 : South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 29 : South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 30 : South Asia & Pacific Market Value (US$ Mn) Forecast by End User, 2017-2032
- Table 31 : MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
- Table 32 : MEA Market Value (US$ Mn) Forecast by Therapy Type, 2017-2032
- Table 33 : MEA Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
- Table 34 : MEA Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
- Table 35 : MEA Market Value (US$ Mn) Forecast by End User, 2017-2032
- Figure 1 : Global Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 2 : Global Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 3 : Global Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 4 : Global Market Value (US$ Mn) by End User, 2022-2032
- Figure 5 : Global Market Value (US$ Mn) by Region, 2022-2032
- Figure 6 : Global Market Value (US$ Mn) Analysis by Region, 2017-2032
- Figure 7 : Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
- Figure 8 : Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
- Figure 9 : Global Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 10 : Global Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 11 : Global Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 12 : Global Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 13 : Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 14 : Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 15 : Global Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 16 : Global Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 17 : Global Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 18 : Global Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 19 : Global Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 20 : Global Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 21 : Global Market Attractiveness by Therapy Type, 2022-2032
- Figure 22 : Global Market Attractiveness by Route of Administration, 2022-2032
- Figure 23 : Global Market Attractiveness by Disease Type, 2022-2032
- Figure 24 : Global Market Attractiveness by End User, 2022-2032
- Figure 25 : Global Market Attractiveness by Region, 2022-2032
- Figure 26 : North America Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 27 : North America Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 28 : North America Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 29 : North America Market Value (US$ Mn) by End User, 2022-2032
- Figure 30 : North America Market Value (US$ Mn) by Country, 2022-2032
- Figure 31 : North America Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 32 : North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 33 : North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 34 : North America Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 35 : North America Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 36 : North America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 37 : North America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 38 : North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 39 : North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 40 : North America Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 41 : North America Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 42 : North America Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 43 : North America Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 44 : North America Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 45 : North America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 46 : North America Market Attractiveness by Therapy Type, 2022-2032
- Figure 47 : North America Market Attractiveness by Route of Administration, 2022-2032
- Figure 48 : North America Market Attractiveness by Disease Type, 2022-2032
- Figure 49 : North America Market Attractiveness by End User, 2022-2032
- Figure 50 : North America Market Attractiveness by Country, 2022-2032
- Figure 51 : Latin America Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 52 : Latin America Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 53 : Latin America Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 54 : Latin America Market Value (US$ Mn) by End User, 2022-2032
- Figure 55 : Latin America Market Value (US$ Mn) by Country, 2022-2032
- Figure 56 : Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 57 : Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 58 : Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 59 : Latin America Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 60 : Latin America Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 61 : Latin America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 62 : Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 63 : Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 64 : Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 65 : Latin America Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 66 : Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 67 : Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 68 : Latin America Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 69 : Latin America Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 70 : Latin America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 71 : Latin America Market Attractiveness by Therapy Type, 2022-2032
- Figure 72 : Latin America Market Attractiveness by Route of Administration, 2022-2032
- Figure 73 : Latin America Market Attractiveness by Disease Type, 2022-2032
- Figure 74 : Latin America Market Attractiveness by End User, 2022-2032
- Figure 75 : Latin America Market Attractiveness by Country, 2022-2032
- Figure 76 : Europe Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 77 : Europe Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 78 : Europe Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 79 : Europe Market Value (US$ Mn) by End User, 2022-2032
- Figure 80 : Europe Market Value (US$ Mn) by Country, 2022-2032
- Figure 81 : Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 82 : Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 83 : Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 84 : Europe Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 85 : Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 86 : Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 87 : Europe Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 88 : Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 89 : Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 90 : Europe Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 91 : Europe Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 92 : Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 93 : Europe Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 94 : Europe Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 95 : Europe Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 96 : Europe Market Attractiveness by Therapy Type, 2022-2032
- Figure 97 : Europe Market Attractiveness by Route of Administration, 2022-2032
- Figure 98 : Europe Market Attractiveness by Disease Type, 2022-2032
- Figure 99 : Europe Market Attractiveness by End User, 2022-2032
- Figure 100 : Europe Market Attractiveness by Country, 2022-2032
- Figure 101 : East Asia Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 102 : East Asia Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 103 : East Asia Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 104 : East Asia Market Value (US$ Mn) by End User, 2022-2032
- Figure 105 : East Asia Market Value (US$ Mn) by Country, 2022-2032
- Figure 106 : East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 107 : East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 108 : East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 109 : East Asia Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 110 : East Asia Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 111 : East Asia Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 112 : East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 113 : East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 114 : East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 115 : East Asia Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 116 : East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 117 : East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 118 : East Asia Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 119 : East Asia Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 120 : East Asia Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 121 : East Asia Market Attractiveness by Therapy Type, 2022-2032
- Figure 122 : East Asia Market Attractiveness by Route of Administration, 2022-2032
- Figure 123 : East Asia Market Attractiveness by Disease Type, 2022-2032
- Figure 124 : East Asia Market Attractiveness by End User, 2022-2032
- Figure 125 : East Asia Market Attractiveness by Country, 2022-2032
- Figure 126 : South Asia & Pacific Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 127 : South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 128 : South Asia & Pacific Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 129 : South Asia & Pacific Market Value (US$ Mn) by End User, 2022-2032
- Figure 130 : South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032
- Figure 131 : South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 132 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 133 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 134 : South Asia & Pacific Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 135 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 136 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 137 : South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 138 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 139 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 140 : South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 141 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 142 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 143 : South Asia & Pacific Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 144 : South Asia & Pacific Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 145 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 146 : South Asia & Pacific Market Attractiveness by Therapy Type, 2022-2032
- Figure 147 : South Asia & Pacific Market Attractiveness by Route of Administration, 2022-2032
- Figure 148 : South Asia & Pacific Market Attractiveness by Disease Type, 2022-2032
- Figure 149 : South Asia & Pacific Market Attractiveness by End User, 2022-2032
- Figure 150 : South Asia & Pacific Market Attractiveness by Country, 2022-2032
- Figure 151 : MEA Market Value (US$ Mn) by Therapy Type, 2022-2032
- Figure 152 : MEA Market Value (US$ Mn) by Route of Administration, 2022-2032
- Figure 153 : MEA Market Value (US$ Mn) by Disease Type, 2022-2032
- Figure 154 : MEA Market Value (US$ Mn) by End User, 2022-2032
- Figure 155 : MEA Market Value (US$ Mn) by Country, 2022-2032
- Figure 156 : MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
- Figure 157 : MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
- Figure 158 : MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
- Figure 159 : MEA Market Value (US$ Mn) Analysis by Therapy Type, 2017-2032
- Figure 160 : MEA Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032
- Figure 161 : MEA Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032
- Figure 162 : MEA Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
- Figure 163 : MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
- Figure 164 : MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
- Figure 165 : MEA Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
- Figure 166 : MEA Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
- Figure 167 : MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
- Figure 168 : MEA Market Value (US$ Mn) Analysis by End User, 2017-2032
- Figure 169 : MEA Market Value Share (%) and BPS Analysis by End User, 2022-2032
- Figure 170 : MEA Market Y-o-Y Growth (%) Projections by End User, 2022-2032
- Figure 171 : MEA Market Attractiveness by Therapy Type, 2022-2032
- Figure 172 : MEA Market Attractiveness by Route of Administration, 2022-2032
- Figure 173 : MEA Market Attractiveness by Disease Type, 2022-2032
- Figure 174 : MEA Market Attractiveness by End User, 2022-2032
- Figure 175 : MEA Market Attractiveness by Country, 2022-2032
Future Market Insights is the premier provider of market intelligence and consulting services, serving client in over 160 countries. FMI is headquartered in London, the global financial capital and has delivery centers in the U.S. and India. FMI's research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure that our clients prepare for the evolving needs of their customers. FMI's team of over 200 research analysts provides market intelligence at global, regional, and country levels. Our analysts are committed to provide independent insights, relying on our cognitive training modules, which conditions them to look at data objectively and unbiasedly. Others you can use from the file Allen just shared when those will be made live.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More